Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1022
Abstract: An intramuscular formulation of aripiprazole monohydrate dosed once monthly (AOM) was developed to address nonadherence with the approved oral tablets. A 3‐compartment linear population pharmacokinetic model for oral and AOM doses was developed; relative bioavailability… read more here.
Keywords: population pharmacokinetic; population; exposure response; metabolizer status ... See more keywords
CYP2C19 Metabolizer Status Does Not Influence the Safety or Efficacy of Pentamidine
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.596
Abstract: Background Pneumocystis jirovecii (PJP) infections are a significant cause of morbidity and mortality in recipients of hematopoietic cell transplantations (HCT), and PJP prophylaxis is a standard of care. The gold standard for PJP prophylaxis is… read more here.
Keywords: metabolizer status; cyp2c19 metabolizer; metabolizer; function ... See more keywords
CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12071187
Abstract: CYP2D6 and CYP2C19 are enzymes of essential significance for the pharmacokinetics of a multitude of commonly used antidepressants, antipsychotics, antiemetics, β-blockers, opioids, antiestrogen, antacids, etc. Polymorphisms in the respective genes are well established as resulting… read more here.
Keywords: cyp2c19; medicine; cyp2d6; metabolizer status ... See more keywords